Loss of the Non-Canonical BAF Complex as a Driver and Therapeutic Target in SF3B1-Mutant MDS and Leukemia

IN PARTNERSHIP WITH LEUKEMIA & LYMPHOMA SOCIETY AND THE PAUL G. ALLEN FRONTIERS GROUP (2020-PRESENT)

Robert Bradley, PhD, Fred Hutchinson Cancer Research Center

Dr. Bradley is investigating comprehensively the mutations in the SF3B1 protein and their connection with myelodysplastic syndromes (MDS) and leukemias and exploring this protein as a therapeutic target.

BACK TO OUR PORTFOLIO